Summary of the Conference Call for Zhaoyan New Drug (2025) Company Overview - **Company**: Zhaoyan New Drug - **Industry**: Pharmaceutical and CRO (Contract Research Organization) Key Financial Performance - **New Orders**: In the first half of 2025, new orders amounted to 1.02 billion yuan, a year-on-year increase of 13.33%. The second quarter saw a single-quarter increase of 18% with new orders of 590 million yuan [2][5] - **Revenue**: Total revenue for the first half was 669 million yuan, with domestic clients contributing 417 million yuan (62.31%) and international clients contributing 252 million yuan (37.69%) [3] - **Net Profit**: The net profit attributable to shareholders was 60.93 million yuan, marking a turnaround from losses in the same period of 2024 [2][3] - **Gross Margin**: The gross margin was reported at 24.03%, down from previous levels due to a decrease in revenue and fewer high-margin long-cycle orders [3][4] Business Developments - **Technological Investments**: The company is investing in drug evaluation technologies, organoids, organ-on-chip technologies, and has seen a significant increase in antibody, small nucleic acid, and ADC project numbers [2][6] - **CMA Certification**: The Suzhou facility has passed CMA certification, allowing it to conduct medical device testing and non-clinical research [2][6] - **Innovation in Domestic Market**: The booming domestic innovative drug business is enhancing international recognition of Chinese innovations, leading to increased R&D investments [2][7] Market Dynamics - **Experimental Monkey Pricing**: Prices for experimental monkeys are stable, with quarterly fair value changes expected to be around 50 million yuan due to natural growth impacts [2][8] - **Offshore Outsourcing**: The company is focusing on expanding its offshore outsourcing business, with a double-digit growth in order numbers, although the total order value remains stable [2][9] Challenges and Risks - **Aging Monkey Population**: The aging population of experimental monkeys in China poses a long-term capacity risk. The company is implementing measures to ensure stable supply and quality [2][10] - **Cost Pressures**: Rising costs due to overseas inflation have led to a decrease in gross margin for international business, which fell to 26% in the first half of 2025 [3][35] Future Outlook - **Capital Expenditure**: The company plans to invest 200 to 300 million yuan in capital expenditures for facility expansions and new laboratory constructions [3][26] - **Order Trends**: The company anticipates a slight decline in overseas orders but aims to maintain overall order levels [3][13] - **Market Positioning**: The company is optimistic about the future of the innovative drug sector in China and plans to continue developing its capabilities in organoid and AI technologies [2][38] Additional Insights - **Client Composition**: In the second quarter, new orders were primarily from biotech companies, which accounted for over 50% of the total, while traditional pharmaceutical companies contributed less than 50% [3][27] - **Impact of FDA Regulations**: The company is monitoring potential impacts from FDA regulations that may reduce animal testing requirements and is prepared to adjust its R&D strategies accordingly [3][17] This summary encapsulates the key points from the conference call, highlighting the financial performance, business developments, market dynamics, challenges, and future outlook for Zhaoyan New Drug.

格隆汇7月30日丨博济医药(300404.SZ)在互动平台表示，公司是一家专业的CRO服务提供商，主要为医 药企业提供医药研发外包服务并收取技术服务费，目前暂无基孔肯雅热病症的项目。 ...

格隆汇7月30日丨博济医药(300404.SZ)在互动平台表示，公司是一家专业的CRO服务提供商，主要为医 药企业提供医药研发外包服务。当前公司在研的药物以创新药为主，涵盖化药、生物药、中药，涉及各 个药物治疗领域。此外，公司还可以提供医疗器械相关的临床试验及注册申报服务。 ...

证券日报网讯博济医药7月29日在互动平台回答投资者提问时表示，公司是一家专业的CRO服务提供 商，主要为医药企业提供医药研发外包服务并收取技术服务费。 （文章来源：证券日报） ...

Core Viewpoint - WuXi AppTec (603259.SH) continues to demonstrate robust growth in its operating performance, with significant increases in revenue and net profit expected for the first half of 2025 [2][3]. Financial Performance - For the first half of 2025, the company anticipates revenue of approximately 20.79 billion yuan, representing a year-on-year growth of about 20.64% [3]. - The expected adjusted net profit for the same period is around 6.315 billion yuan, reflecting a year-on-year increase of approximately 44.43% [3]. - In Q1 2025, the company achieved revenue of 9.655 billion yuan, a year-on-year growth of 20.96%, with net profits of 3.672 billion yuan, marking an impressive growth of 89.06% [3]. Business Model and Strategy - The company focuses on a unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, which is crucial for meeting customer empowerment needs [5]. - WuXi AppTec has positioned itself as one of the few open-access new drug research and development service platforms capable of providing services across the entire new drug development chain [7]. R&D and Capacity Expansion - As of the end of 2024, the company employed approximately 31,800 R&D personnel, accounting for 80.7% of its total workforce [9]. - The company has made significant investments in expanding its production capacity, with new facilities expected to come online in the coming years, including a doubling of oral formulation capacity at its Swiss facility [8]. Client Base and Orders - WuXi AppTec serves around 6,000 active clients, including all of the top 20 global pharmaceutical companies, and has added approximately 1,000 new clients in its ongoing business [8]. - The company reported a backlog of orders in its ongoing business of 49.31 billion yuan at the end of 2024, a year-on-year increase of 47% [8].

Core Viewpoint - 博济医药's 2024 annual report indicates significant revenue growth, but also highlights notable quarterly fluctuations in performance metrics [1] Financial Performance - The company achieved total revenue of 742 million yuan, representing a year-on-year increase of 33.50% [1] - Net profit attributable to shareholders was 28.78 million yuan, up 18.23% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 19.30 million yuan, showing a substantial increase of 92.71% year-on-year [1] - However, there were quarterly declines, with total revenue rolling quarter-on-quarter down by 1.48%, net profit down by 35.47%, and net profit excluding non-recurring items down by 38.24% [1] Revenue Breakdown - Clinical research services revenue reached 597 million yuan, a significant increase of 44.12% year-on-year, with new contract value growing by 38.56% to 1.305 billion yuan [5] - Preclinical research services revenue was 84.32 million yuan, reflecting a growth of 7.70% year-on-year, with new contract value around 158 million yuan [6] - Other consulting services revenue decreased by 13.02% year-on-year to 42.22 million yuan, with new contract value approximately 5.2 million yuan [7] Business Segments - The company continues to lead in traditional areas such as liver disease, oncology, and endocrinology while making breakthroughs in emerging fields like immunology and gene therapy [5] - In the medical device sector, the company conducted nearly 80 clinical research services and 40 registration services, securing 13 Class III medical device registrations [5] - The company has established partnerships with over 900 clinical trial service organizations and signed strategic cooperation agreements with more than 40 institutions [5] R&D and Innovation - The company has received over 10 invention patents and is progressing well with multiple self-research projects [8] - The drug evaluation center successfully passed the GLP qualification re-examination and received the GLP certification [6] - AI technology is being utilized in the design of new target compounds to enhance research efficiency and accuracy [6]